Module 1.3.1 (Pharmacological management of Gout) Flashcards

1
Q

What is gout? How is it classified? What are the two general causes?

A

Increased uric acid in joints

  • >6.4 mg/dl insoluble (average female = 4.1, male = 5.0)

Two general causes

  1. Overproduction of purine nucleotides, giving excessive uric acid
  2. Impaired uric acid excretion through kidneys (drugs/toxins can contribute here)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

The main treatment used to treat gout? What is its MOA?

A

Treat with allopurinol, an analogue of hypoxanthine

  • Strongly inhibits xanthine oxidase.
  • Hypoxanthine reused through salvage pathways indirectly reducing PRPP levels
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the biochemical causes of GOUT?

A
  • Increased PRPP synthetase activity
  • Increased PRPP amidotransferase
  • Decreased HGPRT (partial activity)
  • Decreased glucose 6-phosphatase activity

Deposits in joints –> arthritis

Deposits in kidney –> renal disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

For the drugs used in GOUT;

A) What decreases leukocyte migration into the joint?

B) What decreases uric acid synthesis?

C) What increases uric acid excretion?

A

A)

  • Colchicine

B)

  • Allopurinol or Febuxostat

C)

  • Probenecid, Benzbromarone
  • Non specific anti-inflam & analgesi
  • NSAIDs – except aspirin (NO SALYCYLATES allowed)
  • Corticosteroids
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

For colchicine (acute management of gout);

A) What is it used for?

B) What is its MOA

C) When to give

D) When is relief achieved, peak plasma conc and when is it detectable in leukocytes?

A

A)

  • Acute gouty arthritis: Anti-inflammatory action only
  • Antimitotic - tubulin inhibitor (depolymerisation)

B)

Loss of fibrillar tubules in granulocytes – Inhibits neutrophil migration, chemotaxis, adhesion & phagocytosis in inflamed areas

  • decreased mast cell histamine release
  • decreased production of inflammatory glycoprotein (neutrophils)
  • decreased body temperature
  • decreased respiratory centre
  • decreased collagen formation

C)

  • Give less than or equal to 1 day after attack
  • 80% of patients experience a decrease in joint inflammation

D)

  • Relief in <12hours
  • Peak plasma conc (1-2h)
  • Detectable in leukocytes in 9 days
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are some considerations for colchicine? Is it used prophylactically in chronic gout?

A

Considerations:

  • Gastrointestinal disease
  • Renal impairment
  • Hepatic impairment
  • Pregnancy
  • Elderly

Yes, it is prophylactically used in chronic gout

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the side effects/toxicity of colchicine? Is there less GI effects if IV injection?

A

nausea, vomiting, diarrhoea (80% of patients experience NVD), abdominal pain (GI tract), rash – possible myopathy, bone marrow - leukopenia

  • Less GI effects if IV injection, but narrow therapeutic window – IV –> increased risk of sepsis (death)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the preferred medication to be used in acute gout? Why so? When may colchicine be the better drug?

A
  1. Indomethacin
  2. Ibuprofen
  • Both preferred for acute gouty arthritis –> less side effects especially gastrointestinal
  • High doses needed initially for first day (otherwise recurrent attacks possible)

for HF patients –> colchicine better (no fluid retention effects of the drug)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

For allopurinol

A) MOA

B) Properties

C) CI

D) Prophylactic use?

A

A)

  • Xanthine oxidase inhibitor
  • Decrease uric acid concentration in urine to below solubility

B)

  • Orally absorbed - peak <1 h
  • 2-3 h plasma ½ life
  • Faecal excretion

Active meatbolite 25 h 1/2 life –> renal excreted = oxypurinol

C)

  • nursing mothers
  • children
  • hypersensitive (skin rash with drug)

D)

  • leukaemia, lymphoma, (antineoplastic agent use)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

For Uricosuric Agents;

A) What is its MOA

B) Properties of Probenecid/Benzbromarone

C) Dosage regimen of probenecid? Why are high doses desired?

A

A)

  • Increases rate of uric acid excretion by kidneys

> inhibition of tubular resorption

  • Normally 90% of uric acid reabsorbed

B)

  • no analgesic or anti-inflammatory activity
  • inhibits organic acids from crossing back from the tubule
  • uric acid only endogenous one affected
  • also keeps penicillins, methotrexate, clofibrate in circulation
  • and many NSAIDs
  • Not useful if low kidney function (Cr CL<50%)
  • Plasma ½ life 5-8h (dose-dependent)

C)

  • ~12h duration (use bd)
  • Small doses may actually decrease uric acid excretion
  • High doses needed to increase excretion
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

When acute attack of gout occurs, what to give and what not to give?

A

What to give:

  • Anti-inflammatory agents first (including corticosteroids)

> Not salicylates (contraindication as they can elevate uric acid levels) and also antagonise the action of probenecid and sulfinpyrazone

  • If renally impaired = corticosteroids preferred, reduce allopurinol dose, avoid colchicine, probenecid

What not to give:

  • DO NOT give uricosuric acids or allopurinol (they could increase severity as urate mobilised from joints)
  • Nor ethanol, thiazide diuretics, cyclosporin A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly